Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.
07/26/2021
The Demaria’s lab has a central interest in addressing the molecular mechanisms whereby ionizing radiation modulates tumor immunogenicity, and exploiting this property of radiation to achieve a therapeutic synergy with immunotherapy in pre-clinical tumor models and in cancer patients. We have recently demonstrated that radiation-induced viral mimicry in cancer cells leads to activation of type I interferon via the cGAS/STING pathway. In vivo, this process contributes to the recruitment and activation of conventional dendritic cells type I (cDC1) to the irradiated tumor and promotes cross-priming and activation of tumor-specific T cells. Ongoing work is addressing other pathways that regulate the ability of radiation to generate an in situ tumor vaccine by modulating innate and adaptive immune cells function. In addition, we found that the transcriptional response elicited by radiation-induced DNA damage enhances the expression of immunogenic mutations, and are investigating the radiation-induced changes in the immunopeptidome presented by MHC class I and MHC class II molecules.
Sandra Demaria, MD
Principal Investigator
Sandra Demaria, M.D., a native of Turin, Italy, obtained her M.D. from the University of Turin, and then moved to New York for her post-doctoral training in immunology as a Damon Runyon-Walter Winchell Cancer Research Fund awardee, followed by a residency in anatomic pathology at NYU School of Medicine (NYU SoM). She remained on the faculty at NYU SoM until 2015 raising to the rank of Professor. She is currently Professor of Radiation Oncology and Pathology at Weill Cornell Medicine in New York City. Dr. Demaria is internationally known for her studies demonstrating the synergy of local radiation therapy with different immunotherapeutic agents in pre-clinical models of cancer. She was the first to show that radiotherapy can convert tumors unresponsive to immune checkpoint inhibitors into responsive ones, a finding being translated in several clinical trials at multiple institutions. As a breast cancer pathologist Dr. Demaria has also studied the immunological microenvironment of breast cancer in patients, and therapeutic strategies to modulate the immune infiltrate in preclinical breast cancer models. Her current work is funded by the US National Cancer Institute and by several private foundations. She has held leadership positions in national professional societies, including the Society for Immunotherapy of Cancer (SITC) where she served on the Board, the AACR Cancer Immunology Working Group Steering Committee, and the Radiation Research Society. She serves in the editorial board of several journals, including The Journal of Immunology, Cancer Immunology Research, Clinical Cancer Research, and Journal for ImmunoTherapy of Cancer.
Sheila Spada, Ph.D.
Post-Doctoral Associate
Sheila obtained the B.Sc and M.Sc in Medical Biotechnology at Sapienza, University of Rome and immediately got the qualification as professional biologist at University of Viterbo (Italy). She continued her academic carrier obtaining the PhD in Immunology and Immunopathology at Sapienza and she currently is continuing her studies in Clinical Pathology and Biochemistry at the same University. As PostDoc, she joined Demaria Lab, where she is investigating the immunomodulatory role of exosomes released by cancer cells upon radiotherapy in combination with immunotherapy in anti-tumor immune response. She got the post-doctoral American-Italian Cancer Foundation fellowship for two years. She loves plants and South American literature.
Maud Charpentier, Ph.D.
Post-Doctoral Associate
Maud obtained her PhD in Immunology - Immunotherapy from the University of Nantes, France. She joined Dr Demaria’s Lab in November 2018 as a Postdoctoral associate. Her current research focusses on deciphering the molecular mechanisms of cancer cell intrinsic type I interferon responses induced by radiation therapy and improvement of in vivo tumor anti-tumor responses by combination of radiation therapy and immunotherapy treatments. Using 3D in vitro culture techniques, she is also investigating how hypoxia impacts the radiation therapy induced activation of IFN pathway and anti-tumor immune response. During her free time, her favourite activities include reading, visiting the countless art exhibitions/shows of New York and spending time with her friends and family.
Samantha Van Nest, Ph.D.
Post-Doctoral Associate
Samantha obtained her PhD in Medical Physics at the University of Victoria on Vancouver Island, Canada. Her research interests include developing techniques for the personalization of radiation therapy including spectroscopic and sequencing approaches. As a Postdoctoral Associate with Dr. Demaria, her research investigates the use of primary organoid models for optimizing radiation therapy and immunotherapy combination treatments. She is also developing techniques to use exosome and extracellular vesicles to inform optimal radiation therapy doses for patient treatments. In her free time, you can find Samantha camping in the forests, kayaking, or caving throughout North America.
Ines Mota, Ph.D.
Post-Doctoral Associate
Ines obtained her PhD in Cancer Immunology at the University of Turin, Italy. Her PhD project received funding from the European Union’s Horizon 2020 Maria Sklodowska-Curie Innovative Training Network (ITN) and its area of interest was the development of new immunotherapeutic approaches for ALK-driven Non-Small Cell Lung Cancer (NSCLC). In June 2021, she joined Dr. Demaria’s Lab as a PostDoctoral Associate. Her interest is in poorly immunogenic tumors and irresponsive to immunotherapy, as well as the development of new immunotherapeutic approaches that comprises both basic and translational research. Her current work is focused on the qualitative and quantitative changes in the immunopeptidome presented by MHC-I/II following radiation. During her free time, she enjoys writing small stories, traveling and spending time with friends and family.
Hiro Sato, M.D., Ph.D.
Visiting Research Associate
Hiro is a Radiation Oncologist and obtained his PhD from the Gunma University, Japan. In 2021, he joined Dr. Demaria’s laboratory at Weill Cornell Medicine as Visiting Fellow. He sees the possibility of combining radiotherapy and immunotherapy to cure even metastatic cancer. Thus, he is interested in finding the optimal way of radiotherapy when combined with immunotherapy. His current works is focused on the immune responses induced by radiotherapy in the irradiated cancer cells and surrounding tumor microenvironment (TME). During his free time, he enjoys watching movies, listening music, and reading. He also loves traveling with his wife and two playful kids.
Recent Publications
For a complete list of peer-reviewed publications from Sandra Demaria, please visit here
